Who
Pierre Gravier
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, PTC Therapeutics; Director, Filana Therapeutics.
In numbers
- Trades disclosed
- 25
- Buys
- 1
- Sells
- 7
- Bought
- $199K
- Sold
- $1.6M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 13 Jul 2023
- Last trade
- 14 Jul 2026
- Last filed
- 16 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Jul 2026filed 16 Jul 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $281K3,494 at $80.35 | filing |
| 14 Jul 2026filed 16 Jul 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $281K3,494 at $80.35 | filing |
| 18 Feb 2026filed 20 Feb 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $208K2,992 at $69.36 | filing |
| 18 Feb 2026filed 20 Feb 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $208K2,992 at $69.36 | filing |
| 6 Jan 2026filed 8 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $165K2,139 at $76.95 | filing |
| 6 Jan 2026filed 8 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $165K2,139 at $76.95 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 15 Jul 2025filed 17 Jul 2025 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $124K2,516 at $49.46 | filing |
| 23 May 2025filed 27 May 2025 | FLNA Filana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,500 at $0.00 | filing |
| 20 Feb 2025filed 21 Feb 2025 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $58K1,167 at $50.12 | filing |
| 19 Feb 2025filed 21 Feb 2025 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $59K1,168 at $50.10 | filing |
| 3 Jan 2025filed 7 Jan 2025 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,250 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 16 Jul 2024filed 18 Jul 2024 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $77K2,269 at $34.02 | filing |
| 9 May 2024filed 13 May 2024 | FLNA Filana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 15 Feb 2024filed 16 Feb 2024 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,500 at $0.00 | filing |
| 15 Feb 2024filed 16 Feb 2024 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
News
PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastPTCT · dailypolitical.com · 19 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company StockPTCT · tickerreport.com · 16 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 SharesPTCT · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Pierre Gravier; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.